New study seeks best backup plan for deadly pneumonia in immunocompromised patients
NCT ID NCT07357103
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at which second-choice treatment works best for a serious lung infection called PCP when the usual antibiotic cannot be used due to allergies, side effects, or failure. About 416 adults with weakened immune systems (from HIV, transplants, cancer, or other causes) will be enrolled. The goal is to find the safest and most effective alternative therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCYSTIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New score could help doctors spot fungal pneumonia faster
- Can a lower dose of antibiotics prevent pneumonia just as well after kidney transplant?
- Can a cancer drug wake up immune cells to beat HIV-Related infections?
- Could a common steroid prevent a deadly complication in AIDS patients?
- Could a simple swab replace a lung scope for pneumocystis diagnosis?
- Could a shorter steroid course be just as good for HIV-Related pneumonia?